A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance 2 years later
We aimed to generate a model of cancer-related fatigue (CRF) of clinical importance 2 years after diagnosis of breast cancer building on clinical and behavioral factors and integrating pre-treatment markers of systemic inflammation. Women with stage I-III hormone receptor-positive/human epidermal gr...
Gespeichert in:
Veröffentlicht in: | Annals of oncology 2024-11, Vol.35 (11), p.1048-1060 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1060 |
---|---|
container_issue | 11 |
container_start_page | 1048 |
container_title | Annals of oncology |
container_volume | 35 |
creator | Di Meglio, A. Havas, J. Pagliuca, M. Franzoi, M.A. Soldato, D. Chiodi, C.K. Gillanders, E. Dubuisson, F. Camara-Clayette, V. Pistilli, B. Ribeiro, J. Joly, F. Cottu, P.H. Tredan, O. Bertaut, A. Ganz, P.A. Bower, J. Partridge, A.H. Martin, A.L. Everhard, S. Boyault, S. Brutin, S. André, F. Michiels, S. Pradon, C. Vaz-Luis, I. |
description | We aimed to generate a model of cancer-related fatigue (CRF) of clinical importance 2 years after diagnosis of breast cancer building on clinical and behavioral factors and integrating pre-treatment markers of systemic inflammation.
Women with stage I-III hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer were included from the multimodal, prospective CANTO cohort (NCT01993498). The primary outcome was global CRF of clinical importance [European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 ≥40/100] 2 years after diagnosis (year 2). Secondary outcomes included physical, emotional, and cognitive CRF (EORTC QLQ-FA12). All pre-treatment candidate variables were assessed at diagnosis, including inflammatory markers [interleukin (IL)-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, interferon γ, IL-1 receptor antagonist, tumor necrosis factor-α, and C-reactive protein], and were tested in multivariable logistic regression models implementing multiple imputation and validation by 100-fold bootstrap resampling.
Among 1208 patients, 415 (34.4%) reported global CRF of clinical importance at year 2. High pre-treatment levels of IL-6 (quartile 4 versus 1) were associated with global CRF at year 2 [adjusted odds ratio (aOR): 2.06 (95% confidence interval [CI] 1.40-3.03); P = 0.0002; area under the receiver operating characteristic curve = 0.74]. Patients with high pre-treatment IL-6 had unhealthier behaviors, including being frequently either overweight or obese [62.4%; mean body mass index 28.0 (standard deviation 6.3 kg/m2)] and physically inactive (53.5% did not meet World Health Organization recommendations). Clinical and behavioral associations with CRF at year 2 included pre-treatment CRF [aOR versus no pre-treatment CRF: 3.99 (95% CI 2.81-5.66)], younger age [aOR per 1-year decrement: 1.02 (95% CI 1.01-1.03)], current tobacco smoking [aOR versus never: 1.81 (95% CI 1.26-2.58)], and worse insomnia or pain [aOR per 10-unit increment: 1.08 (95% CI 1.04-1.13), and 1.12 (95% CI 1.04-1.21), respectively]. Secondary analyses indicated additional associations of IL-2 [aOR per log-unit increment: 1.32 (95% CI 1.03-1.70)] and IL-10 [0.73 (95% CI 0.57-0.93)] with global CRF and of C-reactive protein [1.42 (95% CI 1.13-1.78)] with cognitive CRF at year 2. Emotional distress was consistently associated with physical, emotional, and cognitive CRF.
This study proposes a bio-behavioral framewor |
doi_str_mv | 10.1016/j.annonc.2024.07.728 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3088554496</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753424015175</els_id><sourcerecordid>3088554496</sourcerecordid><originalsourceid>FETCH-LOGICAL-c264t-9e7f3ba59ee7161ef621acc60cc43fafb1fe049510930a3ad9a1044187f87fc3</originalsourceid><addsrcrecordid>eNp9kEtLxDAUhYMoOD7-gYss3bTetOkjG0HEFwhu3Ifb9EYztMmYZITBP2-HcS1cuJvvHDgfY1cCSgGivVmX6H3wpqygkiV0ZVf1R2wlmlYVPUhxzFagqrromlqesrOU1gDQqkqt2M8dH1woBvrEbxciTnwOI008WJ52KdPsDHfeTjjPmF3wHDMfImHK3KA3FPno8MOH5BJHP3K7UB9b2ufN5LwzS6ObNyHmPc0rviOMiU-YKV6wE4tTosu_f87eHx_e75-L17enl_u718JUrcyFos7WAzaKqBOtINtWAo1pwRhZW7SDsARSNQJUDVjjqFCAlKLv7HKmPmfXh9pNDF9bSlnPLhmaJvQUtknX0PdNI6VqF1QeUBNDSpGs3kQ3Y9xpAXqvWq_1QbXeq9bQ6UX1Ers9xGhZ8e0o6mQcLXtHF8lkPQb3f8Ev2AaLwQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3088554496</pqid></control><display><type>article</type><title>A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance 2 years later</title><source>Alma/SFX Local Collection</source><creator>Di Meglio, A. ; Havas, J. ; Pagliuca, M. ; Franzoi, M.A. ; Soldato, D. ; Chiodi, C.K. ; Gillanders, E. ; Dubuisson, F. ; Camara-Clayette, V. ; Pistilli, B. ; Ribeiro, J. ; Joly, F. ; Cottu, P.H. ; Tredan, O. ; Bertaut, A. ; Ganz, P.A. ; Bower, J. ; Partridge, A.H. ; Martin, A.L. ; Everhard, S. ; Boyault, S. ; Brutin, S. ; André, F. ; Michiels, S. ; Pradon, C. ; Vaz-Luis, I.</creator><creatorcontrib>Di Meglio, A. ; Havas, J. ; Pagliuca, M. ; Franzoi, M.A. ; Soldato, D. ; Chiodi, C.K. ; Gillanders, E. ; Dubuisson, F. ; Camara-Clayette, V. ; Pistilli, B. ; Ribeiro, J. ; Joly, F. ; Cottu, P.H. ; Tredan, O. ; Bertaut, A. ; Ganz, P.A. ; Bower, J. ; Partridge, A.H. ; Martin, A.L. ; Everhard, S. ; Boyault, S. ; Brutin, S. ; André, F. ; Michiels, S. ; Pradon, C. ; Vaz-Luis, I.</creatorcontrib><description>We aimed to generate a model of cancer-related fatigue (CRF) of clinical importance 2 years after diagnosis of breast cancer building on clinical and behavioral factors and integrating pre-treatment markers of systemic inflammation.
Women with stage I-III hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer were included from the multimodal, prospective CANTO cohort (NCT01993498). The primary outcome was global CRF of clinical importance [European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 ≥40/100] 2 years after diagnosis (year 2). Secondary outcomes included physical, emotional, and cognitive CRF (EORTC QLQ-FA12). All pre-treatment candidate variables were assessed at diagnosis, including inflammatory markers [interleukin (IL)-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, interferon γ, IL-1 receptor antagonist, tumor necrosis factor-α, and C-reactive protein], and were tested in multivariable logistic regression models implementing multiple imputation and validation by 100-fold bootstrap resampling.
Among 1208 patients, 415 (34.4%) reported global CRF of clinical importance at year 2. High pre-treatment levels of IL-6 (quartile 4 versus 1) were associated with global CRF at year 2 [adjusted odds ratio (aOR): 2.06 (95% confidence interval [CI] 1.40-3.03); P = 0.0002; area under the receiver operating characteristic curve = 0.74]. Patients with high pre-treatment IL-6 had unhealthier behaviors, including being frequently either overweight or obese [62.4%; mean body mass index 28.0 (standard deviation 6.3 kg/m2)] and physically inactive (53.5% did not meet World Health Organization recommendations). Clinical and behavioral associations with CRF at year 2 included pre-treatment CRF [aOR versus no pre-treatment CRF: 3.99 (95% CI 2.81-5.66)], younger age [aOR per 1-year decrement: 1.02 (95% CI 1.01-1.03)], current tobacco smoking [aOR versus never: 1.81 (95% CI 1.26-2.58)], and worse insomnia or pain [aOR per 10-unit increment: 1.08 (95% CI 1.04-1.13), and 1.12 (95% CI 1.04-1.21), respectively]. Secondary analyses indicated additional associations of IL-2 [aOR per log-unit increment: 1.32 (95% CI 1.03-1.70)] and IL-10 [0.73 (95% CI 0.57-0.93)] with global CRF and of C-reactive protein [1.42 (95% CI 1.13-1.78)] with cognitive CRF at year 2. Emotional distress was consistently associated with physical, emotional, and cognitive CRF.
This study proposes a bio-behavioral framework linking pre-treatment systemic inflammation with CRF of clinical importance 2 years later among a large prospective sample of survivors of breast cancer.
•34.4% of 1208 stage I-III breast cancer survivors had cancer-related fatigue of clinical importance 2 years after diagnosis.•High pre-treatment levels of the pro-inflammatory cytokine IL-6 were associated with global fatigue 2 years later.•Individuals with high levels of IL-6 had higher BMI and were less physically active than those with lower levels.•Higher pre-treatment IL-2 and IL-10 were also associated with higher and lower likelihood of global fatigue, respectively.•Higher C-reactive protein was associated with higher likelihood of cognitive fatigue.</description><identifier>ISSN: 0923-7534</identifier><identifier>ISSN: 1569-8041</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1016/j.annonc.2024.07.728</identifier><language>eng</language><publisher>Elsevier Ltd</publisher><subject>breast cancer ; cancer-related fatigue ; health behaviors ; inflammatory markers ; survivorship ; symptom management</subject><ispartof>Annals of oncology, 2024-11, Vol.35 (11), p.1048-1060</ispartof><rights>2024 The Author(s)</rights><rights>Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c264t-9e7f3ba59ee7161ef621acc60cc43fafb1fe049510930a3ad9a1044187f87fc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Di Meglio, A.</creatorcontrib><creatorcontrib>Havas, J.</creatorcontrib><creatorcontrib>Pagliuca, M.</creatorcontrib><creatorcontrib>Franzoi, M.A.</creatorcontrib><creatorcontrib>Soldato, D.</creatorcontrib><creatorcontrib>Chiodi, C.K.</creatorcontrib><creatorcontrib>Gillanders, E.</creatorcontrib><creatorcontrib>Dubuisson, F.</creatorcontrib><creatorcontrib>Camara-Clayette, V.</creatorcontrib><creatorcontrib>Pistilli, B.</creatorcontrib><creatorcontrib>Ribeiro, J.</creatorcontrib><creatorcontrib>Joly, F.</creatorcontrib><creatorcontrib>Cottu, P.H.</creatorcontrib><creatorcontrib>Tredan, O.</creatorcontrib><creatorcontrib>Bertaut, A.</creatorcontrib><creatorcontrib>Ganz, P.A.</creatorcontrib><creatorcontrib>Bower, J.</creatorcontrib><creatorcontrib>Partridge, A.H.</creatorcontrib><creatorcontrib>Martin, A.L.</creatorcontrib><creatorcontrib>Everhard, S.</creatorcontrib><creatorcontrib>Boyault, S.</creatorcontrib><creatorcontrib>Brutin, S.</creatorcontrib><creatorcontrib>André, F.</creatorcontrib><creatorcontrib>Michiels, S.</creatorcontrib><creatorcontrib>Pradon, C.</creatorcontrib><creatorcontrib>Vaz-Luis, I.</creatorcontrib><title>A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance 2 years later</title><title>Annals of oncology</title><description>We aimed to generate a model of cancer-related fatigue (CRF) of clinical importance 2 years after diagnosis of breast cancer building on clinical and behavioral factors and integrating pre-treatment markers of systemic inflammation.
Women with stage I-III hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer were included from the multimodal, prospective CANTO cohort (NCT01993498). The primary outcome was global CRF of clinical importance [European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 ≥40/100] 2 years after diagnosis (year 2). Secondary outcomes included physical, emotional, and cognitive CRF (EORTC QLQ-FA12). All pre-treatment candidate variables were assessed at diagnosis, including inflammatory markers [interleukin (IL)-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, interferon γ, IL-1 receptor antagonist, tumor necrosis factor-α, and C-reactive protein], and were tested in multivariable logistic regression models implementing multiple imputation and validation by 100-fold bootstrap resampling.
Among 1208 patients, 415 (34.4%) reported global CRF of clinical importance at year 2. High pre-treatment levels of IL-6 (quartile 4 versus 1) were associated with global CRF at year 2 [adjusted odds ratio (aOR): 2.06 (95% confidence interval [CI] 1.40-3.03); P = 0.0002; area under the receiver operating characteristic curve = 0.74]. Patients with high pre-treatment IL-6 had unhealthier behaviors, including being frequently either overweight or obese [62.4%; mean body mass index 28.0 (standard deviation 6.3 kg/m2)] and physically inactive (53.5% did not meet World Health Organization recommendations). Clinical and behavioral associations with CRF at year 2 included pre-treatment CRF [aOR versus no pre-treatment CRF: 3.99 (95% CI 2.81-5.66)], younger age [aOR per 1-year decrement: 1.02 (95% CI 1.01-1.03)], current tobacco smoking [aOR versus never: 1.81 (95% CI 1.26-2.58)], and worse insomnia or pain [aOR per 10-unit increment: 1.08 (95% CI 1.04-1.13), and 1.12 (95% CI 1.04-1.21), respectively]. Secondary analyses indicated additional associations of IL-2 [aOR per log-unit increment: 1.32 (95% CI 1.03-1.70)] and IL-10 [0.73 (95% CI 0.57-0.93)] with global CRF and of C-reactive protein [1.42 (95% CI 1.13-1.78)] with cognitive CRF at year 2. Emotional distress was consistently associated with physical, emotional, and cognitive CRF.
This study proposes a bio-behavioral framework linking pre-treatment systemic inflammation with CRF of clinical importance 2 years later among a large prospective sample of survivors of breast cancer.
•34.4% of 1208 stage I-III breast cancer survivors had cancer-related fatigue of clinical importance 2 years after diagnosis.•High pre-treatment levels of the pro-inflammatory cytokine IL-6 were associated with global fatigue 2 years later.•Individuals with high levels of IL-6 had higher BMI and were less physically active than those with lower levels.•Higher pre-treatment IL-2 and IL-10 were also associated with higher and lower likelihood of global fatigue, respectively.•Higher C-reactive protein was associated with higher likelihood of cognitive fatigue.</description><subject>breast cancer</subject><subject>cancer-related fatigue</subject><subject>health behaviors</subject><subject>inflammatory markers</subject><subject>survivorship</subject><subject>symptom management</subject><issn>0923-7534</issn><issn>1569-8041</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kEtLxDAUhYMoOD7-gYss3bTetOkjG0HEFwhu3Ifb9EYztMmYZITBP2-HcS1cuJvvHDgfY1cCSgGivVmX6H3wpqygkiV0ZVf1R2wlmlYVPUhxzFagqrromlqesrOU1gDQqkqt2M8dH1woBvrEbxciTnwOI008WJ52KdPsDHfeTjjPmF3wHDMfImHK3KA3FPno8MOH5BJHP3K7UB9b2ufN5LwzS6ObNyHmPc0rviOMiU-YKV6wE4tTosu_f87eHx_e75-L17enl_u718JUrcyFos7WAzaKqBOtINtWAo1pwRhZW7SDsARSNQJUDVjjqFCAlKLv7HKmPmfXh9pNDF9bSlnPLhmaJvQUtknX0PdNI6VqF1QeUBNDSpGs3kQ3Y9xpAXqvWq_1QbXeq9bQ6UX1Ers9xGhZ8e0o6mQcLXtHF8lkPQb3f8Ev2AaLwQ</recordid><startdate>202411</startdate><enddate>202411</enddate><creator>Di Meglio, A.</creator><creator>Havas, J.</creator><creator>Pagliuca, M.</creator><creator>Franzoi, M.A.</creator><creator>Soldato, D.</creator><creator>Chiodi, C.K.</creator><creator>Gillanders, E.</creator><creator>Dubuisson, F.</creator><creator>Camara-Clayette, V.</creator><creator>Pistilli, B.</creator><creator>Ribeiro, J.</creator><creator>Joly, F.</creator><creator>Cottu, P.H.</creator><creator>Tredan, O.</creator><creator>Bertaut, A.</creator><creator>Ganz, P.A.</creator><creator>Bower, J.</creator><creator>Partridge, A.H.</creator><creator>Martin, A.L.</creator><creator>Everhard, S.</creator><creator>Boyault, S.</creator><creator>Brutin, S.</creator><creator>André, F.</creator><creator>Michiels, S.</creator><creator>Pradon, C.</creator><creator>Vaz-Luis, I.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202411</creationdate><title>A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance 2 years later</title><author>Di Meglio, A. ; Havas, J. ; Pagliuca, M. ; Franzoi, M.A. ; Soldato, D. ; Chiodi, C.K. ; Gillanders, E. ; Dubuisson, F. ; Camara-Clayette, V. ; Pistilli, B. ; Ribeiro, J. ; Joly, F. ; Cottu, P.H. ; Tredan, O. ; Bertaut, A. ; Ganz, P.A. ; Bower, J. ; Partridge, A.H. ; Martin, A.L. ; Everhard, S. ; Boyault, S. ; Brutin, S. ; André, F. ; Michiels, S. ; Pradon, C. ; Vaz-Luis, I.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c264t-9e7f3ba59ee7161ef621acc60cc43fafb1fe049510930a3ad9a1044187f87fc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>breast cancer</topic><topic>cancer-related fatigue</topic><topic>health behaviors</topic><topic>inflammatory markers</topic><topic>survivorship</topic><topic>symptom management</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Di Meglio, A.</creatorcontrib><creatorcontrib>Havas, J.</creatorcontrib><creatorcontrib>Pagliuca, M.</creatorcontrib><creatorcontrib>Franzoi, M.A.</creatorcontrib><creatorcontrib>Soldato, D.</creatorcontrib><creatorcontrib>Chiodi, C.K.</creatorcontrib><creatorcontrib>Gillanders, E.</creatorcontrib><creatorcontrib>Dubuisson, F.</creatorcontrib><creatorcontrib>Camara-Clayette, V.</creatorcontrib><creatorcontrib>Pistilli, B.</creatorcontrib><creatorcontrib>Ribeiro, J.</creatorcontrib><creatorcontrib>Joly, F.</creatorcontrib><creatorcontrib>Cottu, P.H.</creatorcontrib><creatorcontrib>Tredan, O.</creatorcontrib><creatorcontrib>Bertaut, A.</creatorcontrib><creatorcontrib>Ganz, P.A.</creatorcontrib><creatorcontrib>Bower, J.</creatorcontrib><creatorcontrib>Partridge, A.H.</creatorcontrib><creatorcontrib>Martin, A.L.</creatorcontrib><creatorcontrib>Everhard, S.</creatorcontrib><creatorcontrib>Boyault, S.</creatorcontrib><creatorcontrib>Brutin, S.</creatorcontrib><creatorcontrib>André, F.</creatorcontrib><creatorcontrib>Michiels, S.</creatorcontrib><creatorcontrib>Pradon, C.</creatorcontrib><creatorcontrib>Vaz-Luis, I.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Di Meglio, A.</au><au>Havas, J.</au><au>Pagliuca, M.</au><au>Franzoi, M.A.</au><au>Soldato, D.</au><au>Chiodi, C.K.</au><au>Gillanders, E.</au><au>Dubuisson, F.</au><au>Camara-Clayette, V.</au><au>Pistilli, B.</au><au>Ribeiro, J.</au><au>Joly, F.</au><au>Cottu, P.H.</au><au>Tredan, O.</au><au>Bertaut, A.</au><au>Ganz, P.A.</au><au>Bower, J.</au><au>Partridge, A.H.</au><au>Martin, A.L.</au><au>Everhard, S.</au><au>Boyault, S.</au><au>Brutin, S.</au><au>André, F.</au><au>Michiels, S.</au><au>Pradon, C.</au><au>Vaz-Luis, I.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance 2 years later</atitle><jtitle>Annals of oncology</jtitle><date>2024-11</date><risdate>2024</risdate><volume>35</volume><issue>11</issue><spage>1048</spage><epage>1060</epage><pages>1048-1060</pages><issn>0923-7534</issn><issn>1569-8041</issn><eissn>1569-8041</eissn><abstract>We aimed to generate a model of cancer-related fatigue (CRF) of clinical importance 2 years after diagnosis of breast cancer building on clinical and behavioral factors and integrating pre-treatment markers of systemic inflammation.
Women with stage I-III hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer were included from the multimodal, prospective CANTO cohort (NCT01993498). The primary outcome was global CRF of clinical importance [European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 ≥40/100] 2 years after diagnosis (year 2). Secondary outcomes included physical, emotional, and cognitive CRF (EORTC QLQ-FA12). All pre-treatment candidate variables were assessed at diagnosis, including inflammatory markers [interleukin (IL)-1α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, interferon γ, IL-1 receptor antagonist, tumor necrosis factor-α, and C-reactive protein], and were tested in multivariable logistic regression models implementing multiple imputation and validation by 100-fold bootstrap resampling.
Among 1208 patients, 415 (34.4%) reported global CRF of clinical importance at year 2. High pre-treatment levels of IL-6 (quartile 4 versus 1) were associated with global CRF at year 2 [adjusted odds ratio (aOR): 2.06 (95% confidence interval [CI] 1.40-3.03); P = 0.0002; area under the receiver operating characteristic curve = 0.74]. Patients with high pre-treatment IL-6 had unhealthier behaviors, including being frequently either overweight or obese [62.4%; mean body mass index 28.0 (standard deviation 6.3 kg/m2)] and physically inactive (53.5% did not meet World Health Organization recommendations). Clinical and behavioral associations with CRF at year 2 included pre-treatment CRF [aOR versus no pre-treatment CRF: 3.99 (95% CI 2.81-5.66)], younger age [aOR per 1-year decrement: 1.02 (95% CI 1.01-1.03)], current tobacco smoking [aOR versus never: 1.81 (95% CI 1.26-2.58)], and worse insomnia or pain [aOR per 10-unit increment: 1.08 (95% CI 1.04-1.13), and 1.12 (95% CI 1.04-1.21), respectively]. Secondary analyses indicated additional associations of IL-2 [aOR per log-unit increment: 1.32 (95% CI 1.03-1.70)] and IL-10 [0.73 (95% CI 0.57-0.93)] with global CRF and of C-reactive protein [1.42 (95% CI 1.13-1.78)] with cognitive CRF at year 2. Emotional distress was consistently associated with physical, emotional, and cognitive CRF.
This study proposes a bio-behavioral framework linking pre-treatment systemic inflammation with CRF of clinical importance 2 years later among a large prospective sample of survivors of breast cancer.
•34.4% of 1208 stage I-III breast cancer survivors had cancer-related fatigue of clinical importance 2 years after diagnosis.•High pre-treatment levels of the pro-inflammatory cytokine IL-6 were associated with global fatigue 2 years later.•Individuals with high levels of IL-6 had higher BMI and were less physically active than those with lower levels.•Higher pre-treatment IL-2 and IL-10 were also associated with higher and lower likelihood of global fatigue, respectively.•Higher C-reactive protein was associated with higher likelihood of cognitive fatigue.</abstract><pub>Elsevier Ltd</pub><doi>10.1016/j.annonc.2024.07.728</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0923-7534 |
ispartof | Annals of oncology, 2024-11, Vol.35 (11), p.1048-1060 |
issn | 0923-7534 1569-8041 1569-8041 |
language | eng |
recordid | cdi_proquest_miscellaneous_3088554496 |
source | Alma/SFX Local Collection |
subjects | breast cancer cancer-related fatigue health behaviors inflammatory markers survivorship symptom management |
title | A bio-behavioral model of systemic inflammation at breast cancer diagnosis and fatigue of clinical importance 2 years later |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T15%3A42%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20bio-behavioral%20model%20of%20systemic%20inflammation%20at%20breast%20cancer%20diagnosis%20and%20fatigue%20of%20clinical%20importance%202%20years%20later&rft.jtitle=Annals%20of%20oncology&rft.au=Di%20Meglio,%20A.&rft.date=2024-11&rft.volume=35&rft.issue=11&rft.spage=1048&rft.epage=1060&rft.pages=1048-1060&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1016/j.annonc.2024.07.728&rft_dat=%3Cproquest_cross%3E3088554496%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3088554496&rft_id=info:pmid/&rft_els_id=S0923753424015175&rfr_iscdi=true |